Accordingly, the monoclonal antibody (mAbs), such as Trastuzumab (Herceptin) [13] and Pertuzumab (Perjeta) [14], and kinase inhibitors such as Laptinib, combined with neoadjuvant chemotherapy, have dramatically increased survival rates in patients with HER2+ breast cancer [15]. Here, ERBB2 is linked to breast cancer.